Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S274100
Reexamination Certificate
active
10380891
ABSTRACT:
Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b).
REFERENCES:
patent: 5236917 (1993-08-01), Dunlap et al.
patent: 5514505 (1996-05-01), Limburg et al.
patent: 5717100 (1998-02-01), Selnick et al.
patent: 5859041 (1999-01-01), Liverton et al.
patent: 2 306 108 (1997-04-01), None
patent: WO 95/03297 (1995-02-01), None
patent: WO96/03387 (1996-02-01), None
patent: WO96/41645 (1996-12-01), None
patent: WO97/36587 (1997-10-01), None
patent: WO97/47618 (1997-12-01), None
patent: WO97/48672 (1997-12-01), None
patent: WO98/16227 (1998-04-01), None
patent: WO98/18788 (1998-05-01), None
patent: WO99/21555 (1999-05-01), None
patent: WO99/25717 (1999-05-01), None
patent: WO00/06124 (2000-11-01), None
Adams J.L. et al, Recent progress towards the idnetification of selective inhibitors of serine/theronine protein kinases, Current Opinion in Drug Discovery and Development 1999 2(2) 96-109.
Adams. J.L et al, Pyrimidinylimidazole Inhibitors of CSBP/p38 Demonstrating Decreased inhibition of Hepatic Cytochrome p450 Enzymes, Bioorganic & Medical Chemistry Letters 8 (1998) 3111-3116.
Antolini M et al, Analogues of 4,5-bis(3,5-Dichlorophenyl)- 2-trifluoromethyl-1H-Imidazole as Potential Antibacterial Agents. Bioorganic & Medical Chemistry Letters 9 (1999) 1023-1028.
Astles P.C. et al, Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) Inhibitors.2.2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as Potent Inhibitors of ACAT, J.Med.Chem. 1996, 39, 1423.
Bilodeau M. T. et al, Solid-supported synthesis of Imidazoles: A Strategy for direct resin-attachment to the Imidazole Core. J. Org. Chem 1998 63. 2800-2801.
Boehm J. C. et al. 1-Substituted 4-Aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-Lipoxygenase and cycloxygenase inhibitory potency, J. Med Chem 1996, 39 3929-3937.
Boehm J. C. et al, New Inhibitors of p38 Kinase, Exp Opinion Ther Patents (2000) 10 (1).
Claiborne C.F. et al, An efficient sythesis of Tertasubstituted Imidazoles from N-(2-Oxo)-amides, Tetrahedron Letters 39, (1998) 8939-8942.
Cuenda A. et al, SB203580 is a specific inhibitor of a MAP Kinase homologue which is stimulated by cellular stresses and interleukin-1, FEBS Letters 364 (1995) 229-233.
Dumas J, et al, 1-Phenyl-5-pyrazolyl Ureas Potent and Selective p38 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters 10 (2000) 2051-2054.
Dumas J, et al, Discovery of a new class of p38 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters 10 (2000) 2047-2050.
Eberwein D, et al, In vivo activity of a Raf kinase inhibitor in human tumor xenograft models, 406 Clinical Cancer Research vol. 6 Nov. 2000 (Supplement) Poster session 17 4547.
Gallagher T.F et al, Regulation of Stressed-Induced Cytokine Production by Pyridinylimidazole: Inhibition of CSBP Kinase; Bioorganic & Medical Chemistry vol. 5 No. 1 pp. 49-64 1997.
Garcia-Echeverria C. et al, ATP Site Directed Competitive and Irreversible Inhibtiors of Protein Kinase, Med Res Reviews 2000, 20(1), 28-57.
Hall-Jackson C.A. et al, Effect of SB203580 on the activity of c-Rafin vitroandin vivoOncogene (1999) 18, 2047-2054.
Heimbrook, D.C. et al; Identification of Potent, Selective Inhibitors of Raf Protein Kinase, Amer. Assoc for Cancer Res New Orleans, vol. 39, p. 558, Apr. 1998.
Henry. J. R., et al, Potent inhibitors of the Map Kinase p38, Bioorganic & Medical Chemistry Letters 8 (1998) 3335-3340.
Henry. J. R., et al, p38 mitogen-activated protein kinase as a target for drug discovery, Drugs of the Future 1999, 24 (12) 1345-1354.
Lackey K et al, The Discovery of Potent cRaf1 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters 10 (2000) 223-226.
Laszlo S.E, et al, Pyrroles and other heterocycles as inhibitors of p38 Kinase, Bioorganic & Medical Chemistry Letters 8 (1998) 2689-2694.
Lee J. C. et al, p 38 Mitogen-Activtated Protein Kinase Inhibitors- Mechanisms and Therapeutic Potentials, Pharmacol Ther. vol. 82. Nos. 2-3 pp. 389-397, 1999.
Lisnock, J et al: Molecular Basis for p38 Protein Kinase Inhibitor Specificity, BioChemistry, 1998, 37, 16573-16581.
Liverton, N.J et al: Design and Synthesis of Potent, Selective and Orally Bioavailable tetrasubstituted Imidazoles of p38 Mitogen Activated Protein Kinase, J. Med Chem 1999 42 2180-2190.
Lowinger, T.B. et al, Discovery of a novel class of potent BRaf kinase inhibitors: Strucutre activity relationships 335 Clinical Cancer Research vol. 6 Nov. 2000 (Supplement) Poster session 13 4533.
P38 Inhibitors based on pyridylurea and pyridylacetoamide templates, Exp Opin. Ther. Patents (2000) 10 (7) 1151-1154.
Revesz L, et al, SAR of 4-Hydroxypiperidine and Hydroxyalkyl Substituted Heterocycles as Novel p38 Map Kinase Inhibitors, Bioorganic & Medical Chemistry Letters 10 (2000) 1261-1264.
Salituro F.G, et al, Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Disease, Current Medicinal Chemistry 1999, 6, 807-823.
Stover D.R et al, Recent Advances in protein Kinase inhibition:Current molecular scaffolds used for inhibitor synthesis. Current Opinion in Drug Discovery and Development 1999 2(4) 274-285.
Toledo L.M. et al, The Structure-Based Design of ATP-site Directed Protein Kinase Inhibitors, Current Medicinal Chemistry 1999, 6, 775-805.
Tong L. et al, A highly specific inhibitor of human p38 MAP Kinase binds in he ATP pocket, Nature Structural Biology vol. 4 No. 4 Apr. 1997 p. 311.
Two Novel structural classes of p38 Kinase inhibitors, Exp Opin. Ther. Patents (1999) 9 (4) 477-480.
Wang Z et al, Structural basis of inhibitor selectivity in MAP Kinases, Stucture Sep. 15, 1998, 6: 1117-1128.
Young P. R. et al, Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase bind in the ATP site, The Journal of Biological Chemistry vol. 272 No. 18 Issue of May 2 pp. 12116-12121 1997.
Dean David Kenneth
Takle Andrew Kenneth
Wilson David Matthew
Hsu Grace C.
Kinzig Charles M.
McCarthy Mary E.
Morris Patricia L.
SmithKline Beecham plc
LandOfFree
Imidazole derivatives as Raf kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazole derivatives as Raf kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole derivatives as Raf kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734131